These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 8003818)
1. Heterogeneous immunoreactivity of frozen human benign and malignant breast lesions to C-MYC and C-Ha-ras cellular oncogenes. Pechoux C; Chardonnet Y; Chignol MC; Noël P Histol Histopathol; 1994 Jan; 9(1):35-44. PubMed ID: 8003818 [TBL] [Abstract][Full Text] [Related]
2. [Human papillomaviruses and cellular oncogenes (c-myc, c-Ha-ras) in cutaneous and mucosal lesions in transplantation recipients]. Pélisson I; Soler C; Chignol MC; Euvrard S; Chardonnet Y Bull Cancer; 1992; 79(5):471-82. PubMed ID: 1330099 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas. Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689 [TBL] [Abstract][Full Text] [Related]
4. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711 [TBL] [Abstract][Full Text] [Related]
5. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420 [TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization. Ohuchi N; Hand PH; Merlo G; Fujita J; Mariani-Costantini R; Thor A; Nose M; Callahan R; Schlom J Cancer Res; 1987 Mar; 47(5):1413-20. PubMed ID: 2434216 [TBL] [Abstract][Full Text] [Related]
7. Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. Spandidos DA; Pintzas A; Kakkanas A; Yiagnisis M; Mahera H; Patra E; Agnantis NJ Anticancer Res; 1987; 7(6):1299-304. PubMed ID: 3327455 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression. Spaventi R; Kamenjicki E; Pecina N; Grazio S; Grazio S; Pavelic J; Kusic B; Cvrtila D; Danilovic Z; Spaventi S In Vivo; 1994; 8(2):183-9. PubMed ID: 7919121 [TBL] [Abstract][Full Text] [Related]
9. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas. Hand PH; Vilasi V; Thor A; Ohuchi N; Schlom J J Natl Cancer Inst; 1987 Jul; 79(1):59-65. PubMed ID: 3298786 [TBL] [Abstract][Full Text] [Related]
10. ras, c-myc and c-erbB-2 oncoproteins in human breast cancer. Spandidos DA; Yiagnisis M; Papadimitriou K; Field JK Anticancer Res; 1989; 9(5):1385-93. PubMed ID: 2574023 [TBL] [Abstract][Full Text] [Related]
11. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. Ohuchi N; Thor A; Page DL; Hand PH; Halter SA; Schlom J Cancer Res; 1986 May; 46(5):2511-9. PubMed ID: 3084069 [TBL] [Abstract][Full Text] [Related]
13. [Joint amplification of c-myc and c-Ha-ras oncogenes in human breast and thyroid cancer cells]. Pluzhnikova GF; Serova OM; Kniazev PG; Fedorov SN; Novikov LB Eksp Onkol; 1987; 9(2):15-7. PubMed ID: 3034547 [TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035 [TBL] [Abstract][Full Text] [Related]
15. Expression of ras and c-myc oncoproteins and hepatitis B surface antigen in human liver disease. Tiniakos D; Spandidos DA; Yiagnisis M; Tiniakos G Hepatogastroenterology; 1993 Feb; 40(1):37-40. PubMed ID: 8462926 [TBL] [Abstract][Full Text] [Related]
16. c-myc and c-Ha-ras cellular oncogenes and human papillomaviruses in benign and malignant cutaneous lesions. Pelisson I; Soler C; Pechoux C; Chignol MC; Viac J; Euvrard S; Chardonnet Y J Dermatol Sci; 1992 Jan; 3(1):56-67. PubMed ID: 1317208 [TBL] [Abstract][Full Text] [Related]
17. Phosphotyrosine, p62 c-myc and p21 c-Ha-ras proteins in colonic epithelium of normal and dimethylhydrazine-treated rats: an immunohistochemical analysis. Schwartz B; Benharroch D; Prinsloo I; Cagnano E; Lamprecht SA Anticancer Res; 1995; 15(1):211-8. PubMed ID: 7537485 [TBL] [Abstract][Full Text] [Related]
18. Ontogeny of Ha-ras and c-myc mRNA levels in rabbit embryo and extraembryonic tissues by quantitative in situ hybridization. Martinoli MG; Lambert RD; Pothier F; Pelletier G Mol Reprod Dev; 1992 Jan; 31(1):1-8. PubMed ID: 1562321 [TBL] [Abstract][Full Text] [Related]
19. A possible role for human papillomaviruses and c-myc, c-Ha-ras, and p53 gene alterations in malignant cutaneous lesions from renal transplant recipients. Pelisson I; Soler C; Chardonnet Y; Euvrard S; Schmitt D Cancer Detect Prev; 1996; 20(1):20-30. PubMed ID: 8907200 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry, in situ hybridization and polymerase chain reaction (PCR) in detecting c-myc expression in human malignancies. Tervahauta AI; Syrjänen SM; Kallio PJ; Syrjänen KJ Anticancer Res; 1992; 12(3):1005-11. PubMed ID: 1622111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]